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ABSTRACT	  Somatic	   mutations	   may	   drive	   tumorigenesis	   or	   lead	   to	   new,	   immunogenic	   epitopes	  (neoantigens).	  	  The	  immune	  system	  is	  thought	  to	  represses	  neoplastic	  growths	  through	  the	   recognition	   of	   neoantigens	   presented	   only	   by	   tumor	   cells.	   To	   study	  mutations	   as	  well	   as	   the	   immune	   response	   to	   mutation-­‐generated	   antigens,	   we	   have	   created	   a	  conditional	   knockin	   mouse	   line	   with	   a	   gene	   encoding,	   5’	   to	   3’,	   yellow	   fluorescent	  protein	   (YFP),	   ovalbumin	   (which	   is	   processed	   to	   the	   immunologically	   recognizable	  peptide,	   SIINFEKL),	   and	   cyan	   fluorescent	   protein	   (CFP),	   or,	   YFP-­‐ovalbumin-­‐CFP.	  	   A	  frame	  shift	  mutation	  has	  been	  created	  at	  the	  5’	  end	  of	  the	  ovalbumin	  gene,	  hence	  YFP	  should	  always	  be	  expressed,	  while	  ovalbumin	  and	  CFP	  should	  only	  be	  expressed	  after	  a	  single	  base	  pair	  deletion	  that	  can	  restore	  the	  frame,	  has	  occurred.	  Experiments	  in	  vitro	  have	   been	   conducted	   to	   test	   whether	   the	   transgene	   behaves	   they	   way	   we	   expect.	  	  Transfection	  of	  EL4	  cells	  with	  the	  transgene	  caused	  cells	  to	  express	  YFP.	  	  After	  growing	  the	   transfected	   cells	   (thus	   allowing	   time	   for	   spontaneous	  mutations),	   populations	   of	  YFP+CFP-­‐	   and	   YFP+CFP+	   cells	   were	   sorted	   and	   grown.	   	   The	   YFP+CFP-­‐	   cells	   did	   not	  present	  SIINFEKL	  on	  H2-­‐Kb	  on	  their	  surfaces,	  while	  YFP+CFP+	  cells	  did;	  this	  was	  tested	  by	  incubating	  the	  cells	  with	  B3Z	  cells,	  which	  respond	  to	  the	  SIINFEKL/H2-­‐Kb	  complex.	  	  The	  mouse	  model	  will	  be	  used	  to	  measure	  the	  rate	  of	  mutation	  in	  the	  transgene	  in	  vivo,	  investigate	  the	  immune	  response	  to	  mutation-­‐generated	  antigens	  in	  a	  growing	  tumor	  in	  a	   live	  host,	   and	   test	   the	  hypothesis	   that	   an	   immune	   response	   to	  neoantigens	  on	  non-­‐transformed	  somatic	  cells	  contributes	  to	  aging.	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INTRODUCTION	  	  RANDOM	  SOMATIC	  MUTATIONS	  ACCUMULATE	  WITH	  AGE	  AND	  IN	  TUMORS	  	   Random	  somatic	  mutations	  occur	  in	  all	  mitotic	  cells	  during	  the	  DNA	  synthesis	  phase	  of	  each	  passage	  through	  the	  cell	  cycle.	  	  Although	  there	  are	  DNA	  repair	  mechanisms	  in	  place	  to	  ensure	  fidelity	  in	  the	  synthesis	  of	  new	  DNA	  strands,	  these	  mechanisms	  do	  not	  work	  with	  complete	  efficiency	  and	  some	  errors	  persist	  in	  the	  new	  strands	  (Echols	  and	  Goodman,	  1991).	  	  Studies	  performed	  in	  cell	  lines	  have	  reported	  that	  random	  mutations	  occur	  at	  a	  rate	  between	  10-­‐9	  and	  10-­‐5	  mutations	  per	  base	  pair	  per	  cell	  division	  (Beckman	  and	  Loeb,	  2005;	  Simpson,	  1997).	  There	  are	  several	  types	  of	  mutations	  that	  occur	  during	  DNA	  synthesis.	  	  Among	  the	  most	  common	  are	  the	  insertion	  of	  an	  incorrect	  base	  leading	  to	  improper	  basepairing,	  the	  insertion	  of	  an	  entirely	  new	  base	  that	  was	  not	  previously	  present,	  and	  the	  deletion	  of	  a	  base	  (Zhang	  and	  Gerstein,	  2003).	  	  Assuming	  they	  occur	  in	  a	  protein-­‐coding	  gene,	  these	  different	  mutations	  can	  have	  vastly	  different	  effects	  on	  the	  structure	  (and	  thus	  the	  function)	  of	  the	  protein.	  	  Base	  pair	  substitutions	  may	  either	  be	  silent	  (not	  change	  the	  amino	  acid	  produced	  from	  the	  altered	  codon)	  or	  may	  cause	  a	  missense	  mutation	  (the	  amino	  acid	  produced	  from	  the	  altered	  codon	  is	  a	  different	  one	  than	  is	  produced	  from	  the	  unaltered	  codon).	  	  Silent	  mutations	  have	  no	  effect	  on	  the	  translated	  protein,	  but	  missense	  mutations	  may.	  	  Depending	  on	  how	  the	  new	  amino	  acid	  in	  the	  protein	  interacts	  with	  the	  others,	  the	  overall	  protein	  structure	  may	  or	  may	  not	  be	  changed.	  	  Insertion	  and	  deletions	  of	  bases	  tend	  to	  have	  a	  greater	  effect	  on	  the	  structure	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of	  the	  mutated	  protein	  because	  they	  cause	  the	  nucleotides	  in	  the	  open	  reading	  frame	  to	  shift	  (hence,	  these	  are	  called	  frameshift	  mutations).	  	  This	  completely	  changes	  the	  codons	  that	  are	  read	  and,	  thus,	  the	  amino	  acids	  that	  are	  transcribed.	  	  Frameshift	  mutations	  tend	  to	  either	  lead	  to	  an	  entirely	  new	  protein	  structure	  or	  a	  truncated	  protein	  product	  from	  the	  generation	  of	  an	  early	  stop	  codon	  (Ogura	  et	  al.,	  2001).	  	  	  A	  particular	  type	  of	  insertion	  and	  deletion	  mutation	  is	  more	  likely	  to	  occur	  in	  mononucleotide	  repeat	  tracts,	  which	  are	  8	  or	  more	  of	  the	  same	  nucleotide	  repeated	  consecutively	  (Stringer	  et	  al.,	  2004;	  see	  Levinson	  and	  Gutman,	  1987).	  	  As	  DNA	  polymerase	  reads	  a	  mononucleotide	  repeat	  tract,	  a	  nucleotide	  in	  either	  the	  new	  strand	  or	  the	  template	  strand	  may	  “slip”	  backward	  (the	  template	  strand	  would	  move	  3’	  to	  5’	  and	  the	  new	  strand	  would	  move	  5’	  to	  3’).	  	  	  Either	  strand	  may	  form	  a	  basepair	  with	  a	  nucleotide	  on	  the	  opposite	  strand	  that	  is	  upstream	  of	  the	  nucleotide	  it	  is	  supposed	  to	  pair	  with.	  	  If	  the	  template	  strand	  slips	  back,	  this	  will	  lead	  to	  a	  deletion	  in	  the	  new	  strand,	  whereas	  if	  the	  strand	  being	  synthesized	  slips	  back,	  it	  will	  have	  an	  insertion.	  	  Several	  trinucleotide	  repeat	  disorders	  are	  caused	  by	  slipped	  strand	  misparing	  mutations	  (Axford	  et	  al.,	  2013),	  including	  Huntington’s	  disease,	  in	  which	  CAG	  trinucleotide	  repeat	  tracts	  are	  expanded	  by	  insertions	  made	  in	  the	  newly	  synthesized	  strand	  (however,	  there	  is	  no	  frameshift	  with	  these	  diseases	  because	  three	  nucleotides	  “slip”	  at	  a	  time).	  	   Mutations	  (especially	  frameshift	  mutations)	  will	  often	  cause	  proteins	  to	  misfold	  and/or	  prevent	  them	  from	  functioning	  properly,	  which	  may	  lead	  to	  apoptosis	  of	  the	  cells	  harboring	  these	  mutations.	  	  However,	  in	  addition	  to	  causing	  various	  forms	  of	  cellular	  dysfunction,	  certain	  mutations	  drive	  tumorigenesis	  (Greenman	  et	  al.,	  2007;	  Stratton	  et	  al.,	  2009)	  and	  have	  been	  shown	  to	  accumulate	  in	  cancers	  (Greenman	  et	  al.,	  
	   8	  
2007;	  Stratton	  et	  al.,	  2009).	  	  Driver	  mutations	  enhance	  the	  survival	  and	  proliferative	  ability	  of	  tumor	  cells.	  	  They	  may	  allow	  a	  tumor	  cell	  to	  evade	  apoptosis	  (Hanahan	  and	  Weinberg,	  2000)	  or	  cell	  cycle	  checkpoints	  (Hanahan	  and	  Weinberg,	  2000).	  	  The	  mutations	  that	  do	  not	  drive	  a	  cell	  into	  malignancy,	  and	  do	  not	  promote	  or	  inhibit	  cell	  division	  or	  survival,	  and	  that	  occur	  randomly	  as	  a	  necessary	  part	  of	  cell	  division,	  are	  called	  “passenger”	  mutations.	  Passenger	  mutations	  also	  occur	  in	  genes	  of	  tumor	  cells	  that	  are	  not	  essential	  to	  the	  cell’s	  transformation	  or	  maintaining	  its	  transformed	  phenotype	  (Greenman	  et	  al.,	  2007).	  	  These	  mutations	  can	  generate	  new	  antigens	  (neoantigens)	  that	  allow	  the	  immune	  system	  to	  distinguish	  cancer	  cells	  from	  non-­‐transformed	  cells	  (Matsushita	  et	  al.,	  2012).	  	  It	  is	  possible	  that	  driver	  mutations	  can	  generate	  neoantigens	  as	  well,	  although	  driver	  mutations	  are	  far	  fewer	  in	  number	  than	  passenger	  mutations,	  and	  so	  may	  account	  for	  a	  very	  small	  minority	  of	  tumor	  neoantigens	  at	  best.	  	  An	  immune	  response	  to	  cancer	  is	  discussed	  in	  the	  next	  section.	  The	  rate	  of	  spontaneous	  somatic	  mutations	  has	  not	  been	  rigorously	  measured	  in	  
vivo	  and	  only	  two	  studies	  have	  approached	  the	  accumulation	  of	  mutations	  (but	  not	  the	  rate	  at	  which	  they	  occur)	  in	  a	  living	  organism	  (Stringer	  et	  al.	  2004;	  Fischer	  and	  Stringer	  2008).	  	  These	  studies	  showed	  that	  mutations	  accumulate	  in	  growing	  tumors	  as	  well	  as	  in	  whole,	  aging	  organisms.	  	  Stringer	  et	  al.	  (2004)	  and	  Fischer	  and	  Stringer	  (2008)	  used	  a	  transgenic	  mouse	  model,	  in	  which	  a	  particular	  mutation	  in	  the	  transgene	  led	  to	  the	  expression	  of	  the	  enzyme,	  human	  placental	  alkaline	  phosphatase	  (hPLAP).	  	  An	  insertion	  of	  7	  guanines	  was	  made	  into	  an	  early	  part	  of	  the	  transgene	  in	  which	  4	  guanines	  were	  already	  present.	  	  This	  insertion	  has	  two	  effects	  on	  the	  transgene.	  	  First,	  this	  will	  create	  a	  frameshift	  mutation	  in	  the	  transgene.	  	  Second,	  these	  11	  guanines	  make	  up	  a	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mononucleotide	  tract,	  which	  are	  prone	  to	  slipped	  strand	  mispairing,	  leading	  to	  either	  an	  insertion	  or	  deletion	  in	  the	  newly	  synthesized	  strand.	  	  When	  a	  deletion	  of	  one	  of	  these	  guanines	  occurs,	  the	  frame	  of	  the	  transgene	  will	  be	  restored	  and	  the	  full	  hPLAP	  will	  be	  transcribed	  and	  translated.	  	  5-­‐bromo-­‐4-­‐chloro-­‐3-­‐indolyl	  phosphate	  and	  nitro	  blue	  tetrazolium	  chloride	  were	  then	  used	  to	  stain	  for	  hPLAP	  activity,	  allowing	  for	  the	  visualization	  of	  cells	  that	  had	  mutated.	  	  In	  both	  tumors	  and	  non-­‐transformed	  aging	  tissues,	  multiple	  factors	  led	  to	  the	  accumulation	  of	  mutant	  cells,	  including	  genomic	  instability	  (single	  mutant	  cells	  were	  observed)	  and	  proliferation	  of	  mutant	  cells	  (detected	  by	  clusters	  of	  mutant	  cells).	  	  In	  the	  study	  of	  aging	  tissues,	  they	  also	  found	  that	  mutant	  cells	  accumulated	  in	  tissues	  with	  age.	  	  Both	  findings	  in	  aged	  tissues	  were	  true	  for	  both	  proliferative	  and	  non-­‐proliferative	  tissues,	  although	  the	  rate	  at	  which	  mutant	  cells	  accumulate	  in	  tissues	  was	  not	  measured.	  	  ANTI-­‐CANCER	  IMMUNITY	  	  	   Cytotoxic	  CD8+	  T	  cells	  are	  the	  primary	  direct	  effectors	  of	  an	  anti-­‐cancer	  immune	  response;	  they	  are	  required	  for	  the	  immune	  system	  to	  reject	  a	  tumor	  (DuPage	  et	  al.	  2012;	  Matsushita	  et	  al.,	  2012).	  	  Antigens	  recognized	  by	  CD8+	  T	  cells	  are	  complexes	  of	  an	  8-­‐11	  amino	  acid	  peptide	  and	  an	  MHC	  class	  I	  molecule.	  	  These	  peptide-­‐MHC	  (pMHC)	  complexes	  are	  recognized	  via	  a	  T-­‐cell	  receptor	  (TCR)	  that	  is	  specific	  to	  one	  cognate	  pMHC	  complex	  (although,	  some	  TCRs	  do	  cross-­‐react	  with	  more	  than	  one	  pMHC	  complex).	  	  TCRs	  can	  interact	  with	  a	  peptide	  only	  if	  it	  is	  presented	  on	  a	  MHC	  molecule	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because	  the	  TCR	  interacts	  with	  amino	  acids	  on	  both	  the	  peptide	  and	  the	  MHC	  molecule;	  free	  peptides	  are	  not	  recognized.	  	  	  	   Peptides	  presented	  on	  MHC	  class	  I	  molecules	  are	  generated	  through	  the	  processing	  of	  either	  endogenously	  synthesized	  or	  exogenously	  acquired	  proteins	  (Neefjes	  et	  al.,	  2011);	  the	  presentation	  of	  the	  former	  is	  termed	  direct	  presentation,	  while	  the	  latter	  can	  only	  be	  presented	  on	  MHC	  class	  I	  by	  cross-­‐presentation.	  	  Endogenous	  proteins	  are	  processed	  and	  presented	  by	  all	  nucleated	  somatic	  cells	  in	  the	  body,	  while	  the	  latter	  can	  only	  be	  presented	  by	  dendritic	  cells	  (DCs),	  though	  it	  is	  not	  clear	  specifically	  which	  subsets	  of	  DCs	  are	  capable	  of	  this	  (Joffre	  et	  al.,	  2012).	  	  Direct	  presentation	  is	  essential	  for	  immune	  surveillance	  by	  T	  cells,	  while	  cross-­‐presentation	  is	  necessary	  for	  the	  priming	  of	  naïve	  T	  cells.	  	  In	  the	  case	  of	  cancer,	  both	  mutated	  and	  non-­‐mutated	  peptides	  will	  be	  presented	  on	  MHC	  class	  I	  (Englehorn	  et	  al.,	  2006).	  	  The	  immune	  system	  distinguishes	  between	  “self”	  (non-­‐mutated)	  and	  “nonself”	  (mutated)	  by	  being	  taught	  not	  to	  respond	  to	  a	  particular	  set	  of	  “self”	  epitopes.	  	  In	  T	  cells,	  this	  occurs	  in	  the	  thymus.	  	  After	  being	  produced	  from	  the	  lymphoid	  lineage	  of	  hematopoietic	  cells,	  immature	  CD4-­‐CD8-­‐	  T	  cells	  migrate	  to	  the	  thymus	  where	  they	  receive	  a	  signal	  to	  rearrange	  the	  genes	  encoding	  each	  chain	  of	  the	  T-­‐cell	  receptor	  (TCR)	  and	  express	  CD4	  and	  CD8.	  	  These	  CD4+CD8+	  cells	  then	  interact	  with	  thymic	  epithelial	  cells	  that	  present	  “self”	  peptide	  antigens	  on	  MHC	  class	  I	  and	  MHC	  class	  II	  molecules.	  	  T	  cells	  that	  recognize	  a	  peptide-­‐MHC	  class	  I	  complex	  will	  receive	  a	  survival	  signal	  and	  a	  signal	  to	  downregulate	  expression	  of	  CD4,	  but	  will	  continue	  to	  express	  CD8.	  	  T	  cells	  that	  recognize	  a	  peptide-­‐MHC	  class	  II	  complex	  will	  also	  receive	  a	  survival	  signal,	  but	  will	  receive	  a	  signal	  to	  downregulate	  CD8,	  and	  instead	  will	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continue	  to	  express	  CD4.	  	  The	  survival	  signals	  are	  only	  received	  provided	  that	  the	  T	  cell	  does	  not	  interact	  with	  the	  thymic	  epithelial	  cells	  with	  too	  high	  avidity	  or	  too	  low	  an	  avidity;	  if	  the	  avidity	  of	  the	  interaction	  does	  not	  fall	  within	  a	  very	  narrow	  range,	  the	  immature	  T	  cell	  will	  not	  receive	  a	  survival	  signal	  and	  will	  apoptose.	  	  About	  2%	  of	  immature	  T	  cells	  survive	  this	  selection	  process	  in	  the	  thymus.	  	  Thus,	  only	  cells	  that	  may	  recognize	  self	  MHC	  molecules,	  but	  cannot	  recognize	  self	  peptides	  presented	  on	  MHC	  survive	  selection	  and	  exit	  the	  thymus	  to	  begin	  circulating	  the	  periphery.	  	  For	  a	  more	  detailed	  discussion	  of	  T-­‐cell	  selection,	  see	  reviews	  by	  Klein	  et	  al.	  (2009)	  and	  Klein	  et	  al.	  (2014).	  It	  has	  been	  hypothesized	  that	  through	  cancer	  immunosurveillance,	  (Burnet,	  1970;	  Burnet,	  1971,	  Dunn	  et	  al.,	  2002)	  circulating	  cytotoxic	  CD8+	  T	  cells	  can	  recognize	  neoantigens	  presented	  on	  MHC	  class	  I	  by	  neoplastic	  cells	  and	  repress	  the	  growth	  of	  neoplasia.	  	  However,	  direct	  evidence	  for	  an	  immune	  against	  mutation-­‐generated	  neoantigens	  presented	  on	  a	  tumor	  growing	  in	  a	  live	  host	  is	  lacking.	  	  This	  has	  been	  approached	  by	  studies	  using	  genetic	  engineering	  models	  to	  simultaneously	  remove	  tumor	  suppressor	  genes	  and	  induce	  the	  expression	  of	  oncogenes	  and	  exogenous	  antigens	  (DuPage	  et	  al.,	  2011;	  DuPage	  et	  al.	  2012).	  	  These	  studies	  do	  show	  that	  tumor-­‐specific	  antigens	  are	  required	  for	  tumor	  rejection	  by	  the	  immune	  system,	  but	  they	  have	  relied	  on	  using	  viral	  vectors	  to	  introduce	  exogenous	  antigens	  into	  tumor,	  not	  mutation-­‐generated	  antigens.	  	  While	  this	  is	  how	  some	  tumor	  antigens	  are	  created	  in	  virus-­‐induced	  tumors	  (which	  means	  these	  antigens	  are	  really	  viral	  antigens),	  the	  vast	  majority	  of	  tumor-­‐specific	  antigens	  do	  not	  arise	  in	  this	  fashion	  and	  instead	  are	  thought	  to	  be	  created	  through	  random	  somatic	  mutations	  in	  tumor	  cells.	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Other	  than	  studies	  that	  genetically	  engineer	  tumors	  to	  express	  exogenous	  tumor-­‐specific	  antigens,	  one	  other	  study	  has	  approached	  the	  issue	  of	  demonstrating	  an	  immune	  response	  against	  mutation-­‐generated	  antigens	  (Matsushita	  et	  al.,	  2012).	  	  This	  study	  sequenced	  the	  exome	  of	  a	  tumor	  cell	  line	  and	  the	  mouse	  strain	  from	  which	  it	  is	  derived	  and	  found	  genetic	  differences	  between	  the	  two.	  	  It	  was	  found	  that	  T	  cells	  responded	  to	  antigens	  derived	  from	  the	  protein	  products	  of	  some	  of	  the	  genetic	  differences	  in	  the	  tumor	  cell	  line,	  which	  presumably	  exist	  because	  of	  random	  mutations	  in	  the	  tumor	  cells.	  	  However,	  the	  antigens	  had	  already	  been	  established	  in	  the	  cell	  line	  and	  were	  not	  generated	  after	  being	  injected	  into	  mice.	  	  More	  mutations	  may	  have	  occurred	  in	  the	  tumor	  cells	  after	  the	  tumor	  challenge	  and	  some	  of	  these	  mutations	  may	  have	  led	  to	  neoantigens.	  	  However,	  the	  immune	  response	  was	  found	  to	  occur	  against	  the	  neoantigens	  that	  had	  been	  established	  prior	  to	  the	  challenge.	  	  Thus,	  an	  immune	  response	  to	  neoantigens	  generated	  in	  a	  tumor	  growing	  in	  a	  live	  host	  was	  not	  tested	  here.	  	  OUTLINE	  OF	  THESIS	  	  
1. Creation	  of	  transgene	  encoding	  YFP-­‐ovalbumin-­‐CFP	  with	  a	  frameshift-­
creating	  polyA	  tract	  between	  YFP	  and	  ovalbumin.	  To	  study	  mutation	  and	  antigens	  generated	  from	  mutation,	  a	  transgenic	  mouse	  line	  will	  be	  created	  with	  a	  a	  gene	  encoding,	  5’	  to	  3’,	  yellow	  fluorescent	  protein	  (YFP),	  	  ovalbumin	  (which	  is	  processed	  to	  the	  immunologically	  recognizable	  peptide,	  SIINFEKL),	  and	  cyan	  fluorescent	  protein	  (CFP),	  or,	  YFP-­‐ovalbumin-­‐CFP.	  	  A	  frame	  shift	  mutation	  has	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been	  created	  at	  the	  5’	  end	  of	  the	  ovalbumin	  gene,	  hence	  YFP	  should	  always	  be	  expressed,	  while	  ovalbumin	  and	  CFP	  should	  only	  be	  expressed	  after	  a	  single	  base	  pair	  deletion	  that	  can	  restore	  the	  frame,	  has	  occurred.	  The	  expression	  of	  CFP	  can	  be	  used	  as	  a	  marker	  for	  mutated	  cells.	  	  Thus	  SIINFEKL	  (within	  ovalbumin)	  can	  only	  be	  generated	  from	  mutation	  and	  is	  a	  neoantigens	  in	  this	  model	  and	  an	  immune	  response	  toward	  it	  can	  be	  monitored.	  	  
2. In	  vitro	  testing	  of	  the	  CAG-­YFP-­m7aOVA-­CFP	  transgene.	  	  Before	  injecting	  the	  transgene	  into	  a	  mouse	  embryo	  to	  create	  a	  transgenic	  line,	  it	  was	  transfected	  into	  cultured	  cells	  and	  tested	  to	  determine	  if	  it	  mutated	  to	  express	  CFP	  and	  present	  the	  SIINFEKL/H2-­‐Kb	  complex	  as	  it	  was	  designed	  to	  do.	  
	  
	  
MATERIALS	  AND	  METHODS	  	  MICE	  AND	  CELL	  LINES	  
	  C57BL/6	   mice	   were	   obtained	   from	   the	   Jackson	   Laboratory.	   	   EL4	   cells	   are	   a	   T	   cell	  lymphoma	  derived	  from	  C57BL/6	  mice;	  these	  were	  obtained	  from	  a	  frozen	  stock	  in	  the	  lab.	   	   B3Z	   cells	   are	   a	   T	   cell	   hybridoma	   with	   a	   TCR	   specific	   to	   the	   SIINFEKL/H2-­‐Kb	  complex	   that	   produce	   β-galactosidase in response to recognition of this antigen. β-
galactosidase will convert the substrate chlorophenol red-	   β-D-galactopyranoside to 
chlorophenol red, which can be detected by measuring the absorbance of the solution the 
	   14	  
cells are in at 570 nm.  B3Z cells were obtained from a frozen stock in the lab and have been 
described by Kanaseki and Shastri (2013). 	  CREATION	  OF	  THE	  CAG-­YFP-­m7a-­OVA-­CFP	  TRANSGENE	  
	  An	  ovalbumin	  (OVA)	  plasmid	  was	  taken	  and	  a	  citrine	  yellow	  fluorescent	  protein	  (YFP)	  plasmid	  was	   placed	   upstream	   of	   OVA	   and	   a	   cerulean	   cyan	   fluorescent	   protein	   (CFP)	  plasmid	  was	  placed	  downstream	  of	  OVA.	  At	  the	  beginning	  of	  the	  OVA	  gene,	  7	  adenines	  have	   been	   inserted	   (YFP-­‐7AOVA-­‐CFP;	   Fig.	   1),	   causing	   a	   frameshift	   and	   nonsense	  mutation,	   allowing	   only	   for	   the	   translation	   of	   YFP.	   This	   insertion	   also	   creates	   a	  mutation-­‐prone	  mononucleotide	  repeat	  tract.	  The	  deletion	  of	  a	  single	  base	  pair	  in	  this	  tract	  will	   restore	   the	   frame,	  making	   translation	  of	   the	   full	  YFP-­‐OVA-­‐CFP	  possible	  (Fig.	  2);	  this	  is	  similar	  to	  the	  model	  used	  by	  Stringer	  et	  al.	  described	  above.	  	  In	  mutated	  cells,	  CFP	  will	  be	  expressed	  and	  processing	  of	  this	  full	  protein	  product	  will	  generate	  the	  H2-­‐Kb-­‐restricted	   epitope,	   SIINFEKL.	   	   Two	   transgenes	   were	   created,	   one	   with	   7	   inserted	  adenines	  and	  another	  with	  only	  6	  inserted	  adenines;	  the	  two	  transgenes	  are	  referred	  to	  as	   the	   7A	   transgene	   and	   6A	   transgene,	   respectively.	   	   The	   6A	   transgene	   mimics	   the	  sequence	  we	  expect	  the	  7A	  transgene	  to	  have	  after	  a	  deletion	  occurs	  in	  the	  region	  of	  11	  repeated	  adenines.	  	   	  The	  transgene	  was	  created	  by	  the	  Gene	  Targeting	  and	  Transgenic	  Facility	  at	  the	  University	  of	  Connecticut	  Health	  Center.	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TRANSFECTION	  
	  Electroporation	  was	  performed	  using	   the	  Amaxa®	  Nucleofector®.	   	  Nucleofection	  kits	  containing	  Nucleofection	  solution	  and	  cuvettes	  were	  purchased	  from	  the	  Lonza	  Group.	  	  Two	   million	   EL4	   cells	   were	   centrifuged	   at	   1500	   rpm	   for	   5	   min	   to	   remove	   medium,	  washed	   in	   phosphate-­‐buffered	   saline	   (PBS),	   and	   resuspended	   in	   100	   µL	   of	  Nucleofection	  solution	  in	  a	  cuvette.	  	  FACS	  ANALYSIS	  	  Cells	  were	  analyzed	  by	  flow	  cytometry	  using	  the	  FACSCalibur	  and	  FACS	  Aria	  II	  (Becton	  Dickinson;	   University	   of	   Connecticut	   Health	   Center	   FACS	   facility).	   	   To	   check	   for	  expression	  of	  YFP	  8	  hours	  after	  transfection,	  medium	  was	  removed	  and	  the	  cells	  were	  washed	   in	   PBS.	   	   After	   washing,	   they	   were	   resuspended	   in	   PBS	   and	   run	   on	   the	  FACSCalibur.	   	   To	   sort	   using	   the	   FACS	   Aria	   II,	   cells	   were	   put	   2%	   FBS	   in	   PBS	   at	   a	  concentration	   of	   20	   x	   106	   cells/mL.	   	   Sorted	   cells	   were	   collected	   in	   10%	   FBS	   in	   PBS.	  	  After	  sorting,	  the	  sorting	  medium	  was	  washed	  off	  and	  the	  cells	  were	  either	  immediately	  used	  in	  a	  B3Z	  assay	  or	  were	  put	  back	  in	  culture.	  	  B3Z	  ASSAY	  	  B3Z	  cells	  are	  used	  to	  detect	  the	  presentation	  of	  the	  SIINFEKL/H2-­‐Kb	  complex.	  	  A	  mixed	  culture	  of	  APCs	  and	  B3Z	  cells	  is	  incubated	  for	  16	  hours.	  	  The	  plate	  is	  centrifuged	  at	  2000	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rpm	  for	  2	  min	  and	  the	  medium	  in	  removed.	  	  The	  cells	  are	  then	  washed	  twice	  with	  PBS.	  	  After	  washing,	   the	   β-­‐galactosidase	   substrate	   CPRG	   is	   added	   to	   the	   cells	   and	   they	   are	  incubated	   for	   2	   hours	   in	   a	   37°C	   (5%	   CO2)	   incubator.	   	   The	   contents	   of	   the	   plate	   are	  sensitive	  to	   light,	  so	  the	  plate	  must	  be	  kept	   in	  the	  dark	  (cover	  with	  aluminum	  foil).	   	   If	  the	   reaction	   mixture	   has	   changed	   from	   yellow	   to	   red/purple	   in	   the	   positive	   control	  wells,	  the	  plate	  can	  be	  measured	  for	  the	  absorbance	  of	  570	  nm	  light.	  	  If	  the	  reaction	  has	  not	  led	  to	  a	  color	  change	  after	  2	  hours,	  the	  incubation	  is	  continued	  at	  room	  temperature	  until	   a	   color	   change	   is	   observed,	   at	   which	   point	   the	   absorbance	   of	   570	   nm	   light	   is	  measured.	  	  MICROINJECTION	  	  A	   transgenic	  mouse	   line	  was	   created	   by	  microinjection	   of	   the	   CAG-­‐YFP-­‐m7aOVA-­‐CFP	  transgene	   into	  a	  C57BL/6	  embryo.	   	  A	  superovulated	   female	  C57BL/6	  mouse	   is	  mated	  with	   a	  male	   C57BL/6	  mouse	   and	   the	   fertilized	   eggs	   are	   harvested.	   	   The	   transgene	   is	  then	   microinjected	   into	   the	   sperm	   pronucleus	   and	   the	   microinjected	   single-­‐cell	  embryos	   are	   put	   into	   a	   surrogate	  mother.	   	   The	  microinjection	  was	   performed	  by	   the	  Gene	  Targeting	  and	  Transgenic	  Facility	  at	  the	  University	  of	  Connecticut	  Health	  Center.	  	  FLUORESCENCE	  MICROSCOPY	  	  Tissues	   were	   harvested	   from	   C57BL/6	   mice,	   fixed	   in	   formalin,	   frozen	   in	   optimum	  freezing	   temperature	   (OCT)	  medium,	   and	   cut	   into	   thin	   sections	  with	   a	   cryostat.	   	   The	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thin	   sections	   were	   placed	   on	   microscope	   slides,	   dehydrated	   ,	   and	   then	   stained	   with	  hemotoxylin	   and	   eosin.	   	   The	   stained	   slides	   were	   imaged	   using	   a	   fluorescence	  microscope.	  Dr.	  Kevin	  Claffey	  helped	  with	  tissue	  sectioning	  and	  imaging	  and	  provided	  the	  fluorescence	  microscope.	  	  	  	  
RESULTS	  	  CREATION	  OF	  A	  CELL	  LINE	  THAT	  EXPRESSES	  THE	  TRANSGENE	  	  	   To	  test	  whether	  the	  transgene	  could	  be	  expressed	  by	  cells	  growing	  in	  culture,	  EL4	  cells	  were	  electroporated	  with	  the	  7A	  transgene.	  	  If	  the	  transgene	  is	  expressed	  by	  the	  transfected	  cells,	  a	  signal	  should	  be	  detected	  when	  they	  are	  analyzed	  by	  the	  FACSCalibur	  in	  the	  channel	  FL1,	  which	  detects	  light	  in	  the	  wavelength	  range	  that	  is	  emitted	  by	  fluorescein	  isothiocyanate	  (FITC).	  	  Following	  transfection,	  the	  cells	  were	  put	  back	  in	  culture	  and	  after	  8	  hours	  in	  culture,	  a	  small	  portion	  were	  taken	  and	  analyzed	  by	  flow	  cytometry	  (Fig.	  3).	  The	  emission	  spectra	  of	  FITC	  and	  YFP	  overlap	  so	  YFP	  can	  also	  be	  detected	  by	  the	  FL1	  channel.	  	  Compared	  to	  untransfected	  cells,	  a	  greater	  signal	  was	  detected	  in	  FL1	  from	  the	  transfected	  cells,	  indicating	  greater	  expression	  of	  YFP.	  	  Thus,	  the	  transgene	  is	  expressed	  by	  the	  in	  vitro	  culture	  of	  EL4	  cells.	  	  	  	   The	  portion	  of	  transfected	  EL4	  cells	  that	  were	  not	  analyzed	  by	  FACS	  was	  kept	  in	  culture	  for	  two	  more	  weeks.	  	  At	  this	  time,	  they	  were	  sorted	  into	  YFP+	  cells	  and	  YFP-­‐	  cells	  (all	  cells	  were	  CFP-­‐).	  	  The	  YFP-­‐	  cells	  were	  discarded	  and	  the	  YFP+	  cells	  were	  grown	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for	  two	  more	  weeks	  before	  being	  analyzed	  by	  FACS	  again	  (Fig.	  4).	  	  This	  analysis	  showed	  three	  populations	  of	  cells:	  	   1. YFP-­‐CFP-­‐	  These	  cells	  are	  probably	  cells	  that	  were	  untransfected	  or	  had	  lost	  the	  transgene	  (e.g.	  because	  it	  did	  not	  integrate	  into	  every	  cell’s	  genome)	  before	  the	  sort.	  	  2. YFP+CFP-­‐	  This	  population	  consists	  of	  cells	  that	  have	  been	  transfected	  (and	  retained	  the	  transgene)	  and	  express	  the	  transgene;	  these	  cells	  have	  not	  mutated	  to	  also	  express	  CFP.	  	  	  	  3. YFP+CFP+	  This	  population	  expresses	  YFP,	  which	  means	  that	  these	  cells	  were	  successfully	  transfected	  with	  the	  transgene.	  	  This	  cell	  population	  also	  expresses	  CFP,	  suggesting	  that	  these	  cells	  underwent	  the	  expected	  deletion	  mutation	  to	  express	  CFP.	  	  If	  this	  is	  the	  case,	  SIINFEKL/H2-­‐Kb	  complexes	  should	  be	  presented	  on	  the	  surfaces	  of	  these	  cells.	  	  However,	  it	  is	  also	  possible	  that	  a	  random	  deletion	  mutation	  occurred	  at	  such	  a	  location	  in	  the	  transgene	  that	  only	  restored	  the	  frame	  of	  the	  CFP-­‐encoding	  portion	  of	  the	  gene.	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ANTIGEN	  PRESENTING	  ABILITY	  OF	  THE	  TRANSGENE-­‐EXPRESSING	  CELL	  LINE	  	  	   To	  test	  whether	  cells	  transfected	  with	  the	  7A	  transgene	  that	  express	  CFP	  were	  also	  capable	  of	  presenting	  SIINFEKL/H2-­‐Kb	  complexes	  on	  their	  surfaces,	  transfected	  cell	  were	  incubated	  with	  B3Z	  cells.	  	  In	  this	  assay,	  EL4	  cells	  served	  as	  the	  antigen	  presenting	  cells	  (APCs)	  to	  the	  B3Z	  cells.	  	  After	  this	  incubation,	  the	  β-­‐galactosidase	  substrate	  CPRG	  was	  added	  to	  the	  cells	  and	  the	  absorbance	  of	  the	  solution	  was	  measured	  at	  570	  nm	  (Fig.	  5).	  	  Four	  different	  APCs	  were	  used	  to	  stimulate	  B3Z	  cells:	  EL4	  cells	  pulsed	  with	  free	  SIINFEKL,	  YFP+CFP-­‐	  EL4	  cells	  that	  were	  transfected	  with	  the	  7A	  transgene,	  YFP+CFP+	  EL4	  cells	  transfected	  with	  the	  7A	  transgene,	  and	  EL4	  cells	  transfected	  with	  the	  6A	  transgene.	  	  The	  YFP+CFP-­‐	  EL4	  cells	  and	  the	  YFP+CFP+	  EL4	  cells	  were	  used	  in	  the	  B3Z	  assay	  immediately	  after	  being	  sorted.	  	  Four	  different	  ratios	  of	  APC	  number	  to	  B3Z	  cell	  number	  were	  used	  in	  each	  condition:	  2	  x	  104,	  4	  x	  104,	  8	  x	  104,	  or	  10	  x	  104	  APCs	  to	  10	  x	  104	  	  B3Z	  cells.	  	  EL4	  cells	  pulsed	  with	  SIINFEKL	  gave	  a	  strong	  response	  that	  was	  not	  titratable	  over	  the	  different	  APC:B3Z	  ratios	  because	  the	  solution	  became	  saturated	  with	  chlorophenol	  red,	  even	  when	  a	  small	  number	  of	  APCs	  was	  used.	  	  YFP+CFP-­‐	  EL4	  cells	  did	  not	  stimulate	  a	  B3Z	  response.	  	  YFP+CFP+	  cells	  gave	  a	  positive	  titratable	  response.	  	  EL4	  cells	  transfected	  with	  the	  6A	  transgene,	  like	  the	  untransfected	  cells	  pulsed	  with	  SIINFEKL,	  gave	  a	  strong	  response.	  	  Theoretically,	  the	  YFP+CFP+	  EL4	  cells	  and	  the	  EL4	  cells	  transfected	  with	  the	  6A	  transgene	  should	  be	  expressing	  the	  same	  transgene,	  however,	  the	  cells	  transfected	  with	  the	  6A	  transgene	  gave	  a	  much	  greater	  response	  that	  the	  YFP+CFP+	  cells.	  	  This	  is	  probably	  because	  the	  cells	  transfected	  with	  the	  6A	  transgene	  had	  been	  transfected	  the	  day	  before,	  fewer	  cells	  had	  lost	  the	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transgene,	  and	  the	  cells	  may	  have	  had	  multiple	  copies	  of	  the	  transgene.	  	  The	  YFP+CFP+	  cells	  had	  been	  transfected	  4	  weeks	  earlier	  and	  while	  they	  were	  probably	  stably	  transfected,	  the	  transgene	  was	  probably	  present	  in	  these	  cells	  at	  a	  much	  lower	  copy	  number	  and	  was	  expressed	  at	  a	  lower	  level	  compared	  to	  the	  6A-­‐transfected	  cells.	  	   	  TISSUES	  OF	  THE	  TRANSGENIC	  MOUSE	  EXPRESS	  THE	  TRANSGENE	  	   	  	   The	  data	  described	  above	  show	  that	  in	  vitro	  the	  transgene	  mutation-­‐dependent	  expression	  of	  CFP	  and	  presentation	  of	  the	  SIINFEKL/H2-­‐Kb	  complex.	  	  To	  o	  create	  a	  transgenic	  mouse	  line,	  the	  7A	  transgene	  was	  microinjected	  into	  a	  C57BL/6	  embryo.	  	  At	  6	  weeks	  of	  age,	  pups	  that	  developed	  from	  these	  embryos	  were	  sacrificed	  and	  their	  tissues	  were	  harvested	  to	  check	  for	  expression	  of	  YFP.	  	  After	  harvesting,	  the	  tissues	  were	  fixed	  overnight	  in	  formalin	  and	  then	  put	  into	  optimum	  cutting	  temperature	  medium	  and	  frozen.	  	  The	  frozen	  tissues	  were	  cut	  using	  a	  cryostat	  and	  the	  thin	  sections	  from	  the	  cutting	  were	  placed	  on	  slides.	  	  The	  slides	  were	  stained	  with	  hematoxylin	  and	  eosin	  and	  were	  imaged	  using	  a	  fluorescence	  microscope.	  	  Lung	  and	  colorectal	  tissue	  of	  the	  transgenic	  mice	  were	  found	  to	  be	  noticeably	  more	  fluorescent	  than	  the	  same	  tissues	  from	  a	  wild	  type	  mouse	  (Fig.	  6).	  	  Because	  the	  transgene	  is	  expressed	  under	  the	  CAG	  promoter	  (chicken	  β-­‐actin	  promoter	  with	  CMV	  enhancer),	  it	  should	  have	  strong,	  global	  expression.	  	  This	  is	  not	  the	  case	  here	  as	  the	  lung	  and	  colon	  of	  the	  transgeneic	  mouse	  were	  the	  only	  two	  tissues	  to	  express	  the	  transgene	  at	  a	  noticeably	  greater	  level	  than	  their	  wild	  type	  counterparts.	  	  This	  is	  probably	  because	  of	  the	  location	  in	  the	  genome	  where	  the	  transgene	  inserted.	  	  The	  microinjection	  method	  of	  creating	  a	  transgenic	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mouse	  line	  does	  not	  allow	  for	  directed	  insertion	  of	  the	  transgene	  into	  the	  genome.	  	  Instead,	  insertion	  occurs	  randomly	  (if	  it	  occurs	  at	  all)	  and	  this	  affects	  the	  level	  of	  expression	  of	  the	  transgene	  and	  may	  lead	  to	  different	  expression	  levels	  in	  different	  tissues,	  which	  was	  observed	  here.	  	  
DISCUSSION	  	   The	  data	  shown	  here	  demonstrate	  that	  the	  CAG-­‐YFP-­‐m7aOVA-­‐CFP	  transgene	  encodes	  mutation-­‐dependent	  expression	  of	  CFP	  and	  presentation	  of	  the	  SIINFEKL/H2-­‐Kb	  complex	  on	  the	  surface	  of	  cells.	  	  In	  vitro,	  it	  can	  be	  used	  as	  another	  tool	  for	  measuring	  the	  mutation	  rate	  of	  cultured	  cells.	  	  In	  vivo,	  the	  transgenic	  mouse	  strain	  carrying	  the	  transgene	  can	  be	  used	  to	  test	  the	  following:	  	   1. Measure	  the	  rates	  of	  spontaneous	  mutations	  in	  various	  somatic	  tissues.	  The	  rate	  of	  somatic	  mutation	  will	  be	  measured	  in	  vivo	  in	  various	  tissues	  by	  using	  confocal	  microscopy	  to	  measure	  CFP	  fluorescence	  at	  different	  time	  points	  in	  the	  mouse’s	  life;	  older	  mice	  (6	  months	  old)	  should	  have	  higher	  levels	  of	  CFP	  fluorescence	  than	  younger	  mice	  (3	  weeks	  old).	  	  Both	  slow-­‐	  (e.g.	  brain	  and	  liver)	  and	  fast-­‐dividing	  tissues	  (e.g.	  colon)	  will	  be	  examined,	  to	  determine	  if	  there	  are	  differences	  in	  mutation	  rate	  related	  to	  proliferative	  rate.	  	   2. Measure	  the	  rates	  of	  spontaneous	  mutations	  in	  a	  tumor	  and	  the	  host	  
immune	  response	  to	  the	  generated	  antigens.	  In	  addition	  to	  non-­‐transformed	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tissues,	  the	  rate	  of	  mutation	  in	  a	  methylcholanthrene-­‐induced	  fibrosarcoma	  in	  the	  transgenic	  mice	  will	  be	  measured	  as	  described	  above.	  	  As	  a	  mutation	  in	  the	  CAG-­‐YFP-­‐m7aOVA-­‐CFP	  transgene	  should	  lead	  to	  MHC	  class	  I	  presentation	  of	  SIINFEKL,	  we	  expect	  an	  immune	  response	  to	  be	  elicited	  against	  cells	  that	  develop	  a	  mutation	  in	  the	  transgene.	  MHC	  class	  I	  tetramers	  will	  be	  used	  to	  determine	  the	  presence	  of	  SIINFEKL-­‐specific	  T	  cells	  in	  the	  tumor	  and	  the	  degree	  to	  which	  infiltration	  of	  the	  tumor	  by	  these	  T	  cells	  occurs.	  	  If	  T	  cells	  are	  not	  found	  this	  may	  suggest	  that	  the	  tumor	  is	  capable	  of	  some	  form	  of	  immunosuppression.	  	  As	  somatic	  mutations	  make	  cancer	  cells	  antigenically	  distinct	  from	  non-­‐transformed	  cells	  of	  the	  same	  tissue	  (Matsushita	  et	  al.,	  2012),	  this	  study	  has	  significant	  bearing	  on	  our	  understanding	  of	  the	  immune	  response	  to	  cancer.	  	  Non-­‐transformed	  cells	  will	  accumulate	  somatic	  mutations	  as	  well,	  albeit	  likely	  fewer	  that	  cancer	  cells,	  and	  these	  mutations	  may	  still	  generate	  new	  epitopes.	  	  Thus,	  in	  the	  future,	  the	  second	  question	  stated	  above	  can	  be	  probed	  in	  non-­‐transformed	  tissues.	  	  If	  evidence	  of	  an	  immune	  response	  is	  found,	  it	  would	  likely	  be	  in	  an	  aged	  mouse	  (an	  older	  mouse	  will	  have	  more	  mutations	  and,	  therefore	  more	  mutation-­‐generated	  epitopes	  than	  a	  younger	  mouse).	  	  We	  would	  then	  ask,	  “Does	  an	  immune	  response	  to	  mutation-­‐generated	  epitopes	  contribute	  to	  the	  damage	  and	  dysfunction	  undergone	  by	  tissues	  with	  age?”	  (Geyer	  et	  al.,	  2013).	  	  Applying	  these	  present	  studies	  in	  the	  context	  of	  aging	  mice	  may	  go	  toward	  giving	  us	  a	  greater	  understanding	  of	  a	  mechanism	  behind	  aging.	  
	  
	  




Figure	  1.	  Construct	  for	  two	  versions	  of	  YFP-­‐ovalbumin-­‐CFP.	   	  The	  left	  panel	  shows	  the	  construct	   when	   a	   seven	   adenine	   tract	   is	   inserted	   between	   YFP	   and	   ovalbumin-­‐CFP,	  leading	   to	  a	   frameshift,	   such	   that	  YFP,	  but	  not	  ovalbumin-­‐CFP,	  will	  be	   translated.	  The	  right	  panel	  shows	  the	  construct	  with	  a	  six	  adenine	  tract	  inserted	  in-­‐frame,	  such	  that	  all	  three	  proteins	  (YFP-­‐ovalbumin-­‐CFP)	  will	  be	  translated.	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  A	  
GAG	   AAA	   	   	   	   ATG	   AAG	   …	   GAG	   AGT	   ATA	   ATC	   AAC	   TTT	   GAA	   AAA	   CTG	  
Glu	   Lys	   	   	   	   Met	   Lys	   …	   Glu	   Ser	   Ile	   Ile	   Asn	   Phe	   Glu	   Lys	   Leu	  
E	   K	   	   	   	   M	   K	   …	   E	   S	   I	   I	   N	   F	   E	   K	   L	  
	  
B	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
GAG	   AAA	   AAA	   AAA	   AAT	   GAA	   GAT	   …	   TGA	   GAG	   TAT	   AAT	   CAA	   CTT	   TGA	   AAA	   ACT	  
Glu	   Lys	   Lys	   Lys	   Asn	   Glu	   Asp	   …	   STOP	   Glu	   Tyr	   Asn	   Gln	   Leu	   STOP	   Lys	   Thr	  
E	   K	   K	   K	   N	   E	   D	   …	   STOP	   E	   Y	   N	   Q	   L	   STOP	   K	   T	  
	  




	   	   	   	   	   	   	   	   	   	   	   	   	   	  
GAG	   AAA	   AAA	   AAA	   	   ATG	   AAG	   …	   GAG	   AGT	   ATA	   ATC	   AAC	   TTT	   GAA	   AAA	   CTG	  
Glu	   Lys	   Lys	   Lys	   	   Met	   Lys	   …	   Glu	   Ser	   Ile	   Ile	   Asn	   Phe	   Glu	   Lys	   Leu	  
E	   K	   K	   K	   	   M	   K	   …	   E	   S	   I	   I	   N	   F	   E	   K	   L	  	  	  	  	  	  
Figure	   2.	   The	   7A	   insertion	   into	   the	   transgene.	   (A)	   Shows	   the	   region	   near	   the	   N-­‐terminus	  of	  ovalbumin	  where	  the	   insertion	  of	   the	  7A	  tract	   (B)	  creates	  a	   frameshift	  or	  the	  6A	  tract	  (C)	  is	  inserted	  in-­‐frame.	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Figure	   3.	   FACS	   analysis	   of	   transfected	   cells.	   	   	   Unttansfected	   EL4	   cells	   or	   EL4	   cells	  transfected	  with	  the	  7A	  transgene	  are	  analyzed	  by	  FACS	  for	  the	  expression	  of	  YFP.	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A	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
B	   	   	   	   	   	   	   C	  
	  
Figure	  4.	  FACS	  analysis	  of	  transfected	  cells	  for	  YFP	  and	  CFP	  expression.	  	  EL4	  cells	  were	  transfected	  with	   the	   7A	   transgene,	   grown	   in	   culture	   for	   2	  weeks,	   at	  which	   time	   they	  were	  analyzed	  by	  FACS	  (A)	  and	  sorted	  into	  YFP+CFP-­‐	  and	  YFP+CFP+	  populations.	  These	  two	  populations	  were	  then	  cultured	  for	  2	  more	  weeks,	  after	  which	  they	  were	  sorted	  to	  remove	  contaminating	  cells	  and	  analyzed	  by	  FACS.	   	  The	  YFP+CFP-­‐	   (B)	  and	  YFP+CFP+	  (C)	  populations	  were	  then	  re-­‐analyzed	  by	  FACS	  to	  confirm	  YFP	  and	  CFP	  expression.	  	  	  	  	  
	   27	  
	  	  	  
	  	  	  	  	  
Figure	   5.	   	   Presentation	   of	   SIINFEKL/H2-­‐Kb	   by	   EL4-­‐7A	   cells	   after	   a	   spontaneous	  mutation.	  	  EL4	  cells	  were	  used	  as	  APCs	  to	  stimulate	  B3Z	  cells.	  	  Titrations	  are	  shown	  for	  four	   different	   ratios	   of	   APCs:B3Z	   cells	   that	   were	   used	   for	   stimulation;	   these	   ratios	  increase	   from	   left	   to	   right	   for	   each	  APC.	   	   Starting	   from	   the	   left,	  EL4	   cells	  pulsed	  with	  SIINFEKL	   were	   used	   as	   a	   control	   to	   show	   that	   B3Z	   cells	   could	   be	   stimulated	   by	  SIINFEKL/H2-­‐Kb.	   	  Second,	  EL4	  cells	   transfected	  with	   the	  6A	  transgene	  (EL4-­‐6A)	  were	  used	   as	   a	   control	   to	   show	   that	   the	   product	   of	   the	   in-­‐frame	   gene	   is	   processed	   to	  SIINFEKL	  and	  presented	  on	  H2-­‐Kb.	  	  Third,	  YFP+CFP-­‐	  EL4	  cells	  that	  had	  been	  transfected	  with	   the	   7A	   construct	   were	   used	   to	   show	   that	   the	   out-­‐of-­‐frame	   construct	   does	   not	  present	  the	  SIINFEKL/H2-­‐Kb	  complex	  (The	  level	  of	  response	  seen	  here	  represents	  the	  background	  response).	  	  Fourth,	  YFP+CFP+	  EL4	  cells	  that	  had	  been	  transfected	  with	  the	  7A	  construct	  (so	  they	  were	  initially	  YFP+CFP-­‐)	  and	  cultured	  for	  4	  weeks	  were	  used	  to	  show	  that	  dividing	  cells	  mutate	  to	  present	  the	  SIINFEKL/H2-­‐Kb	  complex.	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